Open AccessNon-small-cell lung cancer with epidermal growth factor receptor L861Q-L833F compound mutation benefits from both afatinib and osimertinib: A case report
Author(s) -
Yao Zhang,
Jiaxu Shen,
Lin Shen,
Yan Chen,
Lei Lei,
Jia-Lei Wang
Publication year - 2021
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v9.i27.8220
Subject(s) - afatinib , osimertinib , medicine , epidermal growth factor receptor , lung cancer , t790m , erlotinib , cancer research , bevacizumab , mutation , oncology , tyrosine kinase , egfr inhibitors , cancer , chemotherapy , gefitinib , receptor , biology , genetics , gene
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been adopted as the standard of care for non-small cell lung cancer (NSCLC) patients harboring EGFR sensitizing mutations. Besides the two common mutations exon 19 deletion and L858R, which together comprise approximately 85% of EGFR mutations in NSCLC, rare EGFR mutations also exist, including point mutations, deletions, and insertions spanning EGFR exons 18-25. However, the responsiveness of uncommon EGFR mutations to EGFR TKIs remains elusive and attracts increasing interest.